Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Opgen Inc
(NQ:
OPGN
)
0.4600
-0.0300 (-6.12%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Opgen Inc
< Previous
1
2
Next >
OpGen Announces Closing of $7.5 Million Public Offering
January 11, 2023
From
OpGen, Inc.
Via
GlobeNewswire
OpGen Announces Pricing of $7.5 Million Public Offering
January 06, 2023
From
OpGen, Inc.
Via
GlobeNewswire
OpGen Announced 1-for-20 Reverse Stock Split
January 04, 2023
From
OpGen, Inc.
Via
GlobeNewswire
OpGen (NASDAQ: OPGN) Reports Positive Data from Clinical Trial for Unyvero as Diagnostic for UTI
December 13, 2022
OpGen, Inc. (NASDAQ: OPGN) is engaged as a precision medicine company that is focused on developing molecular diagnostics and bioinformatics
Via
Spotlight Growth
OpGen Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel
December 13, 2022
From
OpGen, Inc.
Via
GlobeNewswire
OpGen Reports Third Quarter 2022 Financial Results and Provides Business Update
November 10, 2022
From
OpGen, Inc.
Via
GlobeNewswire
OpGen Announces Preliminary Unaudited Revenue and Cash Position for Third Quarter 2022 and Provides Business Update
October 27, 2022
From
OpGen, Inc.
Via
GlobeNewswire
OpGen to Provide Business Update and Financial Results for the Third Quarter 2022 on November 10th at 4:30 p.m. Eastern Standard Time
October 27, 2022
From
OpGen, Inc.
Via
GlobeNewswire
OpGen Subsidiary Curetis and BioVersys Sign Collaboration Agreement for Clinical Trial Support
October 25, 2022
From
OpGen, Inc.
Via
GlobeNewswire
OpGen Announces Closing of $3.38 Million Registered Direct Offering
October 03, 2022
From
OpGen, Inc.
Via
GlobeNewswire
OpGen Announces Successful Completion of Clinical Trial Enrollment for Unyvero Urinary Tract Infection Panel
October 03, 2022
From
OpGen, Inc.
Via
GlobeNewswire
OpGen Announces $3.38 Million Registered Direct Offering
September 30, 2022
From
OpGen, Inc.
Via
GlobeNewswire
OpGen Subsidiary Ares Genetics GmbH Enters into Collaboration Agreement with the Belgian National Reference Centre for Invasive S. pneumoniae at UZ Leuven
July 26, 2022
From
OpGen, Inc.
Via
GlobeNewswire
OpGen, Inc. (NASDAQ:OPGN) Investor Alert: Investigation over Potential Wrongdoing
February 15, 2022
San Diego, CA -- (SBWIRE) -- 02/15/2022 -- Certain directors of OpGen, Inc are under investigation concerning potential breaches of fiduciary duties.
Via
SBWire
Investigation Announced for Investors in OpGen, Inc. (NASDAQ:OPGN) Shares
December 15, 2021
San Diego, CA -- (SBWIRE) -- 12/15/2021 -- An investigation was announced for investors of OpGen, Inc. (NASDAQ:OPGN) shares over potential securities laws violations by OpGen, Inc.
Via
SBWire
NASDAQ: OPGN Investor Notice: Investigation over Potential Wrongdoing at OpGen, Inc.
November 30, 2021
San Diego, CA -- (SBWIRE) -- 11/30/2021 -- An investigation on behalf of investors in OpGen, Inc. (NASDAQ: OPGN) shares over potential wrongdoing at OpGen, Inc. was announced.
Via
SBWire
OpGen, Inc. (NASDAQ:OPGN) Investor Notice: Investigation over Possible Violations of Securities Laws
November 10, 2021
San Diego, CA -- (SBWIRE) -- 11/10/2021 -- OpGen, Inc is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.